Health · India
Biocon subsidiary receives US FDA approval for Yesintek autoinjector
Biocon's US subsidiary has received supplemental approval from the US Food and Drug Administration (FDA) for Yesintek single-dose prefilled autoinjectors. The approval is for two strengths of the autoinjector, which is used to treat conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. Following the announcement, Biocon shares saw a 2% increase.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): Business Standard, The Economic Times